In our study we used ddPCR to investigate the clinical validity of ctDNA measurements in melanoma patients treated with bevacizumab monotherapy by quantifying BRAF, NRAS and TERT promoter mutations in plasma. This evidence concerns the gene NRAS and melanoma.